HCPCS M1202: Documentation of Reason for Not Prescribing ACE Inhibitor or ARB Therapy - OpenPayer

Summary & Overview

HCPCS M1202: Documentation of Reason for Not Prescribing ACE Inhibitor or ARB Therapy

HCPCS Level II code M1202 documents the patient’s reason(s) for not receiving ACE inhibitor or ARB therapy during a measurement period, for example when a patient declines therapy. This administrative code is used in outpatient and ambulatory care settings to capture documented patient decisions that affect guideline‑recommended medication use. Nationally, accurate use of M1202 matters for quality measurement, performance reporting, and care coordination when charting exceptions to medication prescribing.

Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines how M1202 is applied in clinical documentation, the kinds of benchmarks and quality measure impacts tied to non‑prescription reasons, and the clinical context where the code is used. Readers will find a concise overview of the code’s purpose, typical service and site of service, common modifiers and administrative considerations (where available), and guidance on interpreting M1202 in quality measurement reports. Data not available in the input is noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareM1202HCPCS Level IIACE inhibitorARBmedication decision-makingquality measurementoutpatientclinical documentation

Billing Code Overview

HCPCS Level II code M1202 documents the patient's reason(s) for not prescribing angiotensin‑converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy during the measurement period (for example, patient declined or other patient reasons). This code captures clinician documentation when ACE inhibitor or ARB therapy is considered but not prescribed due to patient preference or patient‑specific reasons.

Service type: Clinical documentation of medication decision-making (reason for not prescribing ACE inhibitor or ARB)
Typical site of service: Outpatient clinic or ambulatory care setting where medication management and shared decision‑making occur

Clinical & Coding Specifications

Clinical Context

A primary care clinician or cardiology clinician documents the reasons an eligible patient was not prescribed an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) during the measurement period. Typical patients include adults with hypertension, diabetes mellitus with albuminuria, or heart failure with reduced ejection fraction who would ordinarily be considered for ACE inhibitor/ARB therapy but have a documented contraindication, intolerance, or declined treatment. The workflow begins during a chronic disease follow-up or medication reconciliation visit: the clinician reviews current diagnoses and medications, assesses indications for ACE inhibitor/ARB therapy, queries the patient about prior adverse reactions or preferences, and documents the rationale for not initiating or continuing therapy (for example, prior angioedema, hyperkalemia, pregnancy, renal artery stenosis concern, significant hypotension, patient refusal). Documentation is entered into the electronic health record problem list and progress note, and the M1202 HCPCS Level II code is appended to the claim to capture the reason(s) for not prescribing ACE inhibitor or ARB during the measurement period. Typical site of service is outpatient clinic, primary care office, cardiology clinic, or nephrology clinic.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	Use when additional documentation supports substantially greater effort for services provided during the visit related to complex medication decision-making or counseling about ACE inhibitor/ARB risks.

HCPCS M1214: Spirometry with Confirmed Airflow Obstruction, Documented and Reviewed

HCPCS-M1259-DIALYSIS-PATIENT-STATUS-FIRST-YEAR

HCPCS M1259: Patient Status Documented Within First Year of Dialysis

HCPCS-M1148-PATIENT-SELF-DISCHARGED-ONGOING-CARE-NOT-POSSIBLE

HCPCS Level II M1148: Ongoing Care Not Possible Due to Patient Self-Discharge

HCPCS-M1433-ORAL-CHEMOTHERAPY-EXPOSURE

HCPCS M1433: Oral Chemotherapy Exposure, 30-Day Window

HCPCS-M1427-BONE-SCAN-MEDICAL-JUSTIFICATION

HCPCS Level II M1427: Documentation of Medical Reason for Bone Scan

HCPCS-M1494-PATIENT-REPORTED-FALL-SINCE-LAST-VISIT

HCPCS Level II M1494: Patient Reported Fall Since Last Visit

HCPCS-M1329-POST-OPERATIVE-ACUTE-PVD-EYE-ENCOUNTER

HCPCS M1329: Post-Operative Encounter for Acute Posterior Vitreous Detachment

HCPCS-M1323-POST-INJECTION-IOP-SCREENING-PLAN-OF-CARE

HCPCS M1323: Post-Injection IOP Screening and Plan of Care

HCPCS-M1371-GLYCEMIC-STATUS-ASSESSMENT-HBA1C-LESS-THAN-7

HCPCS M1371: Glycemic Status Assessment, HbA1c/GMI < 7.0%

HCPCS-M1235-DOCUMENTATION-PRIOR-HCV-TEST

HCPCS M1235: Documentation of Prior HCV Antibody or RNA Test

Showing 1–10 of 356

Taxonomy Code	Specialty	Notes
`207Q00000X`	Family Medicine	Primary care clinicians commonly document medication decisions for hypertension, diabetes, and heart failure.
`207R00000X`	Internal Medicine	Internists manage chronic cardiovascular and renal conditions and document contraindications to ACE inhibitor/ARB therapy.
`207RC0000X`	Cardiology	Cardiologists evaluate indications/contraindications in heart failure and ischemic heart disease patients.
`207RP2900X`	Nephrology	Nephrologists assess renal function, hyperkalemia, and renal artery stenosis concerns impacting ACE inhibitor/ARB use.
`208D00000X`	Emergency Medicine	Emergency clinicians may document acute contraindications (e.g., acute kidney injury, hypotension) during ED encounters.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`I10`	Essential (primary) hypertension	Common indication for ACE inhibitor/ARB therapy; documentation needed if not prescribed.
`E11.21`	Type 2 diabetes mellitus with diabetic nephropathy	ACE inhibitor/ARB often indicated for renal protection; reasons for non-prescription must be documented.
`N18.3`	Chronic kidney disease, stage 3 (moderate)	Renal impairment influences ACE inhibitor/ARB use; specific contraindications or monitoring concerns are documented.
`I50.22`	Chronic systolic (congestive) heart failure	ACE inhibitor/ARB are guideline-directed therapies for HFrEF; omissions require documentation of reason.
`O09.891`	Supervision of other high-risk pregnancy, first trimester	Pregnancy and potential teratogenicity are contraindications to ACE inhibitor/ARB; documentation of avoidance is required.
`T78.3XXA`	Angioedema, initial encounter	History of angioedema from ACE inhibitor is a contraindication and should be documented as the reason for not prescribing.
`E87.5`	Hyperkalemia	Elevated potassium can contraindicate ACE inhibitor/ARB therapy; documentation should note this risk.
`I15.0`	Renovascular hypertension	Concern for bilateral renal artery stenosis or renovascular disease influences withholding ACE inhibitor/ARB and must be documented.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutes	Commonly used for follow-up visits where clinicians document reasons for not prescribing ACE inhibitor/ARB.
`99214`	Office or other outpatient visit for the evaluation and management of an established patient, typically 25 minutes	Used when more complex decision-making and counseling regarding ACE inhibitor/ARB omission is performed and documented.
`99406`	Smoking and tobacco use cessation counseling, intermediate, greater than 3 minutes up to 10 minutes	May be performed during visits addressing cardiovascular risk factors alongside documentation for medication decisions.
`36415`	Collection of venous blood by venipuncture	Often performed before or during visits to assess renal function or potassium prior to deciding about ACE inhibitor/ARB therapy.
`81002`	Urinalysis non-automated without microscopy	Used to assess proteinuria or albuminuria as part of evaluating indications for ACE inhibitor/ARB therapy.

OpenPayer